Compare

Biohaven Ltd. vs BGM Group Ltd. vs Enliven Therapeutics, Inc. vs MoonLake Immunotherapeutics

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Biohaven Ltd. BHVN	BGM Group Ltd. BGM	Enliven Therapeutics, Inc. ELVN	MoonLake Immunotherapeutics MLTX
Year ended	2025-12-31	2025-09-30	2025-12-31	2025-12-31
Revenue	n/a	$37.92M	n/a	n/a
Revenue growth (YoY)	n/a	+51.1%	n/a	n/a
Gross margin	n/a	16.6%	n/a	n/a
Operating margin	n/a	-33.2%	n/a	n/a
Net margin	n/a	-52.6%	n/a	n/a
Net income	-$738.82M	-$19.94M	-$103.69M	-$227.32M
EPS (Diluted)	-$6.86	-$0.18	-$1.83	-$3.53
Operating cash flow	-$609.44M	-$2.37M	-$70.30M	-$196.01M
Free cash flow	-$610.15M	-$3.94M	-$70.46M	-$196.04M
Cash & equivalents	$229.96M	$9.82M	$98.90M	$334.52M
Total assets	$451.45M	$433.81M	$476.17M	$424.43M
Total liabilities	$399.38M	$41.92M	$16.57M	$119.95M
Shareholders' equity	$52.07M	$391.90M	$459.60M	$304.48M
Return on year-end equity	n/m	-5.1%	-22.6%	-74.7%
Shares outstanding	132.78M	200.62M	59.44M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Biohaven Ltd.	BGM Group Ltd.	Enliven Therapeutics, Inc.	MoonLake Immunotherapeutics
Latest	n/a	$37.92M Ended 2025-09-30	n/a	n/a
1 year earlier	n/a	$25.10M Ended 2024-09-30	n/a	n/a
2 years earlier	n/a	$46.47M Ended 2023-09-30	n/a	n/a
3 years earlier	n/a	$64.86M Ended 2022-09-30	n/a	n/a
4 years earlier	n/a	$57.10M Ended 2021-09-30	n/a	n/a